Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Files An 8-K Other Events

ME Staff 8-k
-
0

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Files An 8-K Other Events
ITEM 8.01.Other Events.

On July 24, 2017, Amphastar Pharmaceuticals, Inc. (“Amphastar”) announced in a press release that a federal jury delivered a unanimous verdict in favor of the Company in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc. in the U.S. Court for the District of Massachusetts.

A copy of the press release is being filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

ITEM 9.01.Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo.

Description

99.1

Press Release of Amphastar Pharmaceuticals, Inc. dated July 24, 2017


Amphastar Pharmaceuticals, Inc. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 amph_Ex99_1   Exhibit 99.1 Amphastar Announces Jury Verdict in Patent Litigation against Momenta Pharmaceuticals,…
To view the full exhibit click here

About Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.